About Trevor G. Blake
Author of Three Simple Steps, Trevor Blake, knows a thing or two about breaking the mold. Born into poverty, he developed a knack for entrepreneurialism when riding the school bus at the age of twelve. Noting how much his classmates enjoyed sweets, he bought a bulk supply of treats one day and sold them to his fellow travelers. With money in his hand at the end of the day, he learned a thing or two about taking initiative.
Blake has translated his entrepreneurial gifts into a successful career in the pharmaceutical industry. With an MBA from Durham University (UK), and a degree in radiation physics and nuclear medicine, Blake was also a graduate of Britannia Royal Navy College, where he became the first person in his province ever to be awarded a reserved place. Blake has over 20 years of experience as a commercial development leader with successful biotechnology and pharmaceutical companies. This led to his definitive success in 2002 as founder and CEO of America’s most successful “non-employer business,” QOL Medical LLC, a company focused on solutions for rare diseases that he started with just a few thousand dollars. By 2008, QOL was earning $20 million a year in revenues with gross profits of >83%, while developing five medicines used to treat rare diseases, mostly in children. Despite having no facility or employees, QOL provided medicines all over the world, and also set up a compassionate use program that allowed over 25% of patients to receive free medication and allowed no patient to pay more than a $30 co-pay. QOL sold in 2010 for over $100 million. Blake also founded ANU Oncology in 2006, a unique virtually-structured company focused on developing cancer treatments, which he sold in 2011 to Taiwan-based New Pacific for an undisclosed fee. Blake retains a 33% stake in the ensuing joint-venture, Neovia Oncology Ltd.(www.neoviaoncology.com)
Blake’s most recent success has been his New York Times bestselling Three Simple Steps: A Map to Success in Business and Life, (BenBella Books, 2012), which has led to coverage from Wall Street Journal, Publisher’s Weekly, Shape magazine, PBS TV’s Between the Lines, Forbes.com, Inc.com, Blogcritics, and many more media outlets.